BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst John McNulty maintains an Outperform rating on Chemours (NYSE:CC) but lowers the price target from $35 to $30.
August 06, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BMO Capital maintains an Outperform rating on Chemours but lowers the price target from $35 to $30.
The Outperform rating suggests continued confidence in Chemours' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100